The case for & against
Bull & Bear analysis
ImmuneBio, Inc. (NASDAQ: INMB) is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies targeting serious diseases, particularly neurodegenerative disorders such as Alzheimer's and conditions associated with epidermolysis bullosa. The company operates two significant therapeutic platforms: EXPRO for Alzheimer's disease and Cordstrom for recessive dystrophic epidermolysis bullosa (RDEB). Strategically positioned in the high unmet medical need segment of biotechnology, ImmuneBio aims to redefine treatment paradigms by harnessing immunotherapy approaches.
Bull says
- ↑EXPRO Phase II expanded early Alzheimer’s patient pool from 40% to 70%.
- ↑Cordstrom MAA planned for mid-2026, targeting RDEB patients with no systemic treatments.
- ↑Constructive FDA feedback ahead of EXPRO end-of-phase-II meeting boosts approval odds.
- ↑$24.8 M cash runway into Q1 2027 supports key clinical milestones.
- ↑Neuroinflammation focus differentiates EXPRO amid heavy Alzheimer’s competition.
- ↑Dividend yield of 0.36% and positive macro sensitivities suggest stable funding.
Bear says
- ↓2025 net loss grew to $45.9 M from $42.1 M, raising cash burn concerns.
- ↓MINDFUL Alzheimer’s trial missed its top-line endpoint, denting EXPRO outlook.
- ↓R&D spend fell to $20.7 M from $33.2 M, risking slower pipeline progress.
- ↓FDA data gaps could delay EXPRO and Cordstrom submission timelines.
- ↓Biogen and Eli Lilly’s entrenched Alzheimer’s drugs heighten competitive risk.
- ↓Negative earnings yield and weak profitability metrics underscore valuation pressure.
Investment themes with INMB
Genetic and drug innovations driving medical breakthroughs
Stocks with highest short interest
Earnings Call · Q1 2025 · Mgmt. Guidance
Transcript signals
Bull points
- We saw no adverse events in any of the patients treated during phase one, which thus met the primary endpoint of the entire trial.
- none of the patients treated in Phase 2 to date has shown any adverse event, and IncMune remains extremely well tolerated in this challenging and elderly group of patients who've had lots of previous treatment and a lot of comorbidities.
- The CarePC trial continues to recruit Phase II subjects and remains on track to complete enrollment this year.